Table 1.

K_D and K_D(FcγRIIIa)/K_D(FcγRIIb) ratios of rituximab variants

Rituximab variants	KD for FcγRI (mol/L)	KD for FcγRIIb (mol/L)	KD for FcγRIIIaF158 (mol/L)	KD for FcγRIIIaV158 (mol/L)	KD for FcγRIIaH131 (mol/L)	KD for FcγRIIaR131 (mol/L)	KD for FcRn pH 6 (mol/L)	KD for FcRn pH 7.4 (mol/L)	KD(FcγRIIIaF158)/KD(FcγRIIb)	KD(FcγRIIIaV158)/KD(FcγRIIb)
WT	8.67E-09	2.41E-06	9.44E-07	4.03E-07	1.09E-06	1.25E-06	2.10E-08	NB	0.39	0.17
H268E/K326M/I332E	5.15E-09	1.05E-06	1.58E-07	6.91E-08	8.82E-07	7.38E-07	2.60E-08	NB	0.15	0.07
H268E/K326S/I332E	5.18E-09	1.13E-06	1.51E-07	7.47E-08	8.14E-07	8.03E-07	2.50E-08	NB	0.13	0.07
H268E/K326I/I332E	6.11E-09	1.69E-06	3.11E-07	1.43E-07	1.95E-06	1.21E-06	2.57E-08	NB	0.18	0.08
H268E/A330Y/I332D	5.04E-09	1.47E-06	9.40E-08	6.06E-08	5.26E-07	6.8E-07	2.19E-08	NB	0.06	0.04
H268E/A330T/I332E	5.64E-09	9.06E-07	1.56E-07	6.11E-08	6.27E-07	5.75E-07	2.15E-08	NB	0.17	0.07

NB, no measurable binding.